Navigation Links
UPDATE: Celebrating UC Success Announces Essay Contest Winners
Date:5/12/2008

pportive Family Members/Friends and Healthcare Providers. Every applicant was recognized for their entry and received a complimentary one-year membership to the Foundation. Semi-finalists received a $50 gift card to the Foundation's online store.

About Ulcerative Colitis

UC involves inflammation of the lining of the colon and rectum. It varies in clinical severity with patients having mild, moderate or severe disease. Treatment depends on the extent and severity of disease.

UC causes flares followed by periods of remission. During a flare, in which the rectum or colon become inflamed, people experience symptoms such as diarrhea, rectal bleeding, abdominal cramping and an urgent need to go to the bathroom. Flares can vary in duration and intensity. While UC is a lifelong condition, medication may help control flares.

UC affects people of all ages, but is often diagnosed during early adulthood. The causes of this condition are unknown, but may involve heredity, infection and/or the immune system.

About Crohn's & Colitis Foundation of America

The Crohn's & Colitis Foundation of America's mission is to cure Crohn's disease and ulcerative colitis, and to improve the quality of life of children and adults affected by these diseases. The Foundation ranks third among leading health non-profit organizations in the percentage of expense devoted to research toward a cure, and more than 83 cents of every dollar the Foundation spends goes to mission-critical programs. The Foundation consistently meets the standards of organizations that monitor charities, including the Better Business Bureau's Wise Giving Alliance (give.org) and the American Institute of Philanthropy (charitywatch.org). For more information, contact the Foundation at 800-932-2423 or visit http://www.ccfa.org.

About Procter & Gamble (NYSE:

SOURCE The Crohn's & Colitis Foundation of America
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine news :

1. UPDATE: Retirement Living TV Partners With Maryland Public Television to Address the Issue of Healthcare in America Through Its Series Healthcare 08: Search for Solutions
2. VoIP-PAL.com, Inc. (Pink Sheets: VPLM.PK - News) UPDATE: Announces First Award Recipient of TalkfortheCure(TM) Dollars
3. Update: Oscar-Nominated Actress Signs on as Neutrogena(R) Brand Ambassador
4. Skin Cancer Prevention Update:
5. Update: SpineMark Expands Management Team to Build Spine Care Network
6. UPDATE: Governor Rendell to Fight to Cover All Pennsylvanians During Statewide Bus Tour
7. PA Game Commission: EHD Outbreak Update: Test Results Confirm EHD In Beaver County
8. Marriage & Family: Celebrating Holiday Traditions
9. Smilebox and Lifetime Television Promote Breast Cancer Awareness With Multimedia Designs for Sending Mammogram Reminders and Celebrating Courage
10. 14th Annual Parkinsons Unity Walk Most Successful Event to Date
11. MGH researchers report successful new laser treatment for vocal-cord cancer
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 2Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 3Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 4Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 5Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 2Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 3Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 4Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 5Q-Med AB and Oceana Therapeutics, Inc. Take Major Step Towards SOLESTA(TM) US Regulatory Filing 2Q-Med AB and Oceana Therapeutics, Inc. Take Major Step Towards SOLESTA(TM) US Regulatory Filing 3Want to Stop Cancer 3F You Can Experts Say 47763 1Want to Stop Cancer 3F You Can Experts Say 47763 2Want to Stop Cancer 3F You Can Experts Say 47763 3New Ad Campaign Asks D C Commuters Whos Hogging Our Antibiotics 3F 47760 1New Ad Campaign Asks D C Commuters Whos Hogging Our Antibiotics 3F 47760 2Lilly Resubmits Cymbalta 28R 29 Supplemental New Drug Application for Chronic Pain to U S Food and Drug Administration 47758 1Lilly Resubmits Cymbalta 28R 29 Supplemental New Drug Application for Chronic Pain to U S Food and Drug Administration 47758 2Lilly Resubmits Cymbalta 28R 29 Supplemental New Drug Application for Chronic Pain to U S Food and Drug Administration 47758 3Lilly Resubmits Cymbalta 28R 29 Supplemental New Drug Application for Chronic Pain to U S Food and Drug Administration 47758 4